Table 2. Prophylaxis for EBV-induced PTLD (or treatment for increased EBV DNA levels)
EBV-specific T cell activatorT cell sourceProphylaxis forEBV-specific pathologyReferences
LCLTransplant donor derivedPost-HSCT PTLD0/101 developed PTLDRooney et al., 1995, 1998; Heslop et al., 1996, 2010
5/6 exhibited a decrease in EBV DNAGustafsson et al., 2000
1/4 decrease in EBV DNAComoli et al., 2007
AllogeneicPost-HSCT PTLD0/1 showed evidence of viral activation (EBV, CMV, ADV)Naik et al., 2016
DCs + LCLs transduced with ADVTransplant donor derivedPost-HSCT PTLD0/1 showed evidence of viral activation (EBV, CMV, ADV)
DCs + LCLs transduced with ADV + CMV pp65Transplant donor derivedPost-HSCT PTLD0/2 showed evidence of viral activation (EBV, CMV, ADV)
AllogeneicPost-HSCT PTLD0/3 showed evidence of viral activation (EBV, CMV, ADV)
Viral Ags from EBV, CMV, ADVTransplant donor derivedPost-HSCT PTLD0/2 showed evidence of viral activation (EBV, CMV, ADV)

Abbreviations used: ADV, adenovirus.